The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma

Clive S. Zent, Wei D Ding, Susan M. Schwager, Megan S. Reinalda, James Hoyer, Diane F Jelinek, Renee C. Tschumper, Deborah A. Bowen, Timothy G. Call, Tait D. Shanafelt, Neil Elliot Kay, Susan L Slager

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

The development of cytopenia in chronic lymphocytic leukaemia (CLL) patients can predict poor prognosis. All CLL patients seen in the Division of Hematology at Mayo Clinic Rochester from 1 January 1995 to 31 December 2004 (n = 1750) were evaluated for cytopenia, aetiology of cytopenia and clinical outcome. Cytopenia occurred in 423 (24.2%) patients and was attributable to CLL in 303 (17.3%) cases, with 228 (75%) of these having bone marrow (BM) failure and 75 (25%) having autoimmune disease (AID). Survival from onset of cytopenia was significantly better for patients with AID (median 9.1 years) compared to patients with BM failure (median 4.4 years, P < 0.001). Patients with AID diagnosed within 1 year of the diagnosis of CLL (n = 35) had similar survival from diagnosis compared to patients without CLL-related cytopenia (median 9.3 vs. 9.7 years, P = 0.881). Although cytopenia caused by BM failure predicted a poorer prognosis in CLL, cytopenia caused by AID was not an adverse prognostic factor. These findings suggest that patients with cytopenia due to AID cannot be meaningfully classified by the current clinical staging systems. Revisions of the National Cancer Institute Working Group 96 criteria should consider the aetiology of cytopenia in staging CLL patients.

Original languageEnglish (US)
Pages (from-to)615-621
Number of pages7
JournalBritish Journal of Haematology
Volume141
Issue number5
DOIs
StatePublished - Jun 2008

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Autoimmune Diseases
Bone Marrow
Survival
National Cancer Institute (U.S.)
Hematology

Keywords

  • Anaemia
  • Autoimmune cytopenia
  • Chronic lymphocytic leukaemia
  • Prognosis
  • Thrombocytopenia

ASJC Scopus subject areas

  • Hematology

Cite this

The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma. / Zent, Clive S.; Ding, Wei D; Schwager, Susan M.; Reinalda, Megan S.; Hoyer, James; Jelinek, Diane F; Tschumper, Renee C.; Bowen, Deborah A.; Call, Timothy G.; Shanafelt, Tait D.; Kay, Neil Elliot; Slager, Susan L.

In: British Journal of Haematology, Vol. 141, No. 5, 06.2008, p. 615-621.

Research output: Contribution to journalArticle

Zent, Clive S. ; Ding, Wei D ; Schwager, Susan M. ; Reinalda, Megan S. ; Hoyer, James ; Jelinek, Diane F ; Tschumper, Renee C. ; Bowen, Deborah A. ; Call, Timothy G. ; Shanafelt, Tait D. ; Kay, Neil Elliot ; Slager, Susan L. / The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma. In: British Journal of Haematology. 2008 ; Vol. 141, No. 5. pp. 615-621.
@article{1a494eac646a48609578e1b7ea0e743b,
title = "The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma",
abstract = "The development of cytopenia in chronic lymphocytic leukaemia (CLL) patients can predict poor prognosis. All CLL patients seen in the Division of Hematology at Mayo Clinic Rochester from 1 January 1995 to 31 December 2004 (n = 1750) were evaluated for cytopenia, aetiology of cytopenia and clinical outcome. Cytopenia occurred in 423 (24.2{\%}) patients and was attributable to CLL in 303 (17.3{\%}) cases, with 228 (75{\%}) of these having bone marrow (BM) failure and 75 (25{\%}) having autoimmune disease (AID). Survival from onset of cytopenia was significantly better for patients with AID (median 9.1 years) compared to patients with BM failure (median 4.4 years, P < 0.001). Patients with AID diagnosed within 1 year of the diagnosis of CLL (n = 35) had similar survival from diagnosis compared to patients without CLL-related cytopenia (median 9.3 vs. 9.7 years, P = 0.881). Although cytopenia caused by BM failure predicted a poorer prognosis in CLL, cytopenia caused by AID was not an adverse prognostic factor. These findings suggest that patients with cytopenia due to AID cannot be meaningfully classified by the current clinical staging systems. Revisions of the National Cancer Institute Working Group 96 criteria should consider the aetiology of cytopenia in staging CLL patients.",
keywords = "Anaemia, Autoimmune cytopenia, Chronic lymphocytic leukaemia, Prognosis, Thrombocytopenia",
author = "Zent, {Clive S.} and Ding, {Wei D} and Schwager, {Susan M.} and Reinalda, {Megan S.} and James Hoyer and Jelinek, {Diane F} and Tschumper, {Renee C.} and Bowen, {Deborah A.} and Call, {Timothy G.} and Shanafelt, {Tait D.} and Kay, {Neil Elliot} and Slager, {Susan L}",
year = "2008",
month = "6",
doi = "10.1111/j.1365-2141.2008.07086.x",
language = "English (US)",
volume = "141",
pages = "615--621",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma

AU - Zent, Clive S.

AU - Ding, Wei D

AU - Schwager, Susan M.

AU - Reinalda, Megan S.

AU - Hoyer, James

AU - Jelinek, Diane F

AU - Tschumper, Renee C.

AU - Bowen, Deborah A.

AU - Call, Timothy G.

AU - Shanafelt, Tait D.

AU - Kay, Neil Elliot

AU - Slager, Susan L

PY - 2008/6

Y1 - 2008/6

N2 - The development of cytopenia in chronic lymphocytic leukaemia (CLL) patients can predict poor prognosis. All CLL patients seen in the Division of Hematology at Mayo Clinic Rochester from 1 January 1995 to 31 December 2004 (n = 1750) were evaluated for cytopenia, aetiology of cytopenia and clinical outcome. Cytopenia occurred in 423 (24.2%) patients and was attributable to CLL in 303 (17.3%) cases, with 228 (75%) of these having bone marrow (BM) failure and 75 (25%) having autoimmune disease (AID). Survival from onset of cytopenia was significantly better for patients with AID (median 9.1 years) compared to patients with BM failure (median 4.4 years, P < 0.001). Patients with AID diagnosed within 1 year of the diagnosis of CLL (n = 35) had similar survival from diagnosis compared to patients without CLL-related cytopenia (median 9.3 vs. 9.7 years, P = 0.881). Although cytopenia caused by BM failure predicted a poorer prognosis in CLL, cytopenia caused by AID was not an adverse prognostic factor. These findings suggest that patients with cytopenia due to AID cannot be meaningfully classified by the current clinical staging systems. Revisions of the National Cancer Institute Working Group 96 criteria should consider the aetiology of cytopenia in staging CLL patients.

AB - The development of cytopenia in chronic lymphocytic leukaemia (CLL) patients can predict poor prognosis. All CLL patients seen in the Division of Hematology at Mayo Clinic Rochester from 1 January 1995 to 31 December 2004 (n = 1750) were evaluated for cytopenia, aetiology of cytopenia and clinical outcome. Cytopenia occurred in 423 (24.2%) patients and was attributable to CLL in 303 (17.3%) cases, with 228 (75%) of these having bone marrow (BM) failure and 75 (25%) having autoimmune disease (AID). Survival from onset of cytopenia was significantly better for patients with AID (median 9.1 years) compared to patients with BM failure (median 4.4 years, P < 0.001). Patients with AID diagnosed within 1 year of the diagnosis of CLL (n = 35) had similar survival from diagnosis compared to patients without CLL-related cytopenia (median 9.3 vs. 9.7 years, P = 0.881). Although cytopenia caused by BM failure predicted a poorer prognosis in CLL, cytopenia caused by AID was not an adverse prognostic factor. These findings suggest that patients with cytopenia due to AID cannot be meaningfully classified by the current clinical staging systems. Revisions of the National Cancer Institute Working Group 96 criteria should consider the aetiology of cytopenia in staging CLL patients.

KW - Anaemia

KW - Autoimmune cytopenia

KW - Chronic lymphocytic leukaemia

KW - Prognosis

KW - Thrombocytopenia

UR - http://www.scopus.com/inward/record.url?scp=43449088848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43449088848&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2008.07086.x

DO - 10.1111/j.1365-2141.2008.07086.x

M3 - Article

C2 - 18373706

AN - SCOPUS:43449088848

VL - 141

SP - 615

EP - 621

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 5

ER -